Mark Ebbert

5.7k citations

61 papers · 4.0k · 1 hit paper · h-index 28

Impact in

Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 5%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research

Papers in

Cancer Research 7
- Breast Cancer Treatment Studies 7
Neurology 7
- Amyotrophic Lateral Sclerosis Research 6

Co-authors: Philip Seth Bernard (7 shared papers)Inge J. Stijleman (5 shared papers)Perry G. Ridge (16 shared papers)Bryan E. Welm (2 shared papers)Rachel E. Factor (2 shared papers)Brett A. Milash (1 shared paper)Robert Lor Randall (1 shared paper)Saundra S. Buys (1 shared paper)
Journals: BMC Genomics (6 papers)BMC Bioinformatics (3 papers)Molecular Neurodegeneration (3 papers)Journal of Clinical Virology (2 papers)Bioinformatics (2 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Mark Ebbert

58 papers receiving 3.9k citations

Mark Ebbert's Hit Papers

align trajectories log scale

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes 2011 · 822 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2011 Nature Medicine

Peers

Countries citing papers authored by Mark Ebbert

Since Specialization

Citations

This map shows the geographic impact of Mark Ebbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ebbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ebbert more than expected).

Fields of papers citing papers by Mark Ebbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ebbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ebbert. The network helps show where Mark Ebbert may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Ebbert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Ebbert Line = papers co-authored together Mark Ebbert links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes Nature Medicine ·Yoko S. DeRose, Guoying Wang, Yi‐Chun Lin, Philip Seth Bernard, Saundra S. Buys, Mark Ebbert, Rachel E. Factor, Cindy Brown Matsen Hit paper breakdown →	2011	822
2	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer Clinical Cancer Research ·Torsten O. Nielsen, Joel S. Parker, Samuel C. Y. Leung, David Voduc, Mark Ebbert, Tammi L. Vickery, Sherri Davies, Jacqueline Snider	2010	623
3	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers BMC Medical Genomics ·Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert, Aleix Prat, Blanca Munárriz, Leslie R. Rowe, Patricia A. Miller, Manuel Ruíz‐Borrego	2012	263
4	Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis Nature Medicine ·Yong‐Jie Zhang, Tania Gendron, Mark Ebbert, Aliesha D. O’Raw, Mei Yue, Karen R. Jansen‐West, Xu Zhang, Mercedes Prudencio	2018	232
5	Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau The Journal of Experimental Medicine ·Silvia S. Kang, Mark Ebbert, Kelsey E. Baker, Casey N. Cook, Xuewei Wang, Jonathon P. Sens, Jeanne-Pierre Kocher, Leonard Petrucelli	2018	183
6	Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight Genome biology ·Mark Ebbert, Tanner D. Jensen, Karen R. Jansen‐West, Jonathon P. Sens, Joseph S. Reddy, Perry G. Ridge, John S. K. Kauwe, Véronique Belzil	2019	127
7	Curated variation benchmarks for challenging medically relevant autosomal genes Nature Biotechnology ·Justin Wagner, Nathan D. Olson, Lindsay N. Harris, Jennifer McDaniel, Haoyu Cheng, Arkarachai Fungtammasan, Yih-Chii Hwang, Richa Gupta	2022	123
8	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial Clinical Cancer Research ·Maggie Chon U Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel C. Y. Leung, Stephen Chia, Lois E. Shepherd, Mark N. Levine	2012	121
9	Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches BMC Bioinformatics ·Mark Ebbert, Mark E. Wadsworth, Lyndsay A. Staley, Kaitlyn L. Hoyt, Brandon D. Pickett, Justin B. Miller, John Duce, John S. K. Kauwe	2016	113
10	Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics Cancer Epidemiology Biomarkers & Prevention ·Carol Sweeney, Philip Seth Bernard, Rachel E. Factor, Marilyn L. Kwan, Laurel A. Habel, Charles Quesenberry Jr, Kaylynn Shakespear, Erin K. Weltzien	2014	107
11	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer Breast Cancer Research and Treatment ·Cynthia X. Ma, Matthew Ellis, Gina R. Petroni, Zhanfang Guo, Shi-Rong Cai, Christine E. Ryan, Albert Craig Lockhart, Michael J. Naughton	2012	98
12	Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients Human Molecular Genetics ·Mercedes Prudencio, Patrick K. Gonzales, Casey N. Cook, Tania Gendron, Lillian M. Daughrity, Yuping Song, Mark Ebbert, Marka van Blitterswijk	2017	94
13	Long-read sequencing across the C9orf72 ‘GGGGCC’ repeat expansion: implications for clinical use and genetic discovery efforts in human disease Molecular Neurodegeneration ·Mark Ebbert, Stefan L. Farrugia, Jonathon P. Sens, Karen R. Jansen‐West, Tania Gendron, Mercedes Prudencio, Ian J. McLaughlin, Brett N. Bowman	2018	94
14	Genetics of Alzheimer’s Disease BioMed Research International ·Perry G. Ridge, Mark Ebbert, John S. K. Kauwe	2013	79
15	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Breast Cancer Research and Treatment ·M Casado Martín, Aleix Prat, Álvaro Rodríguez-Lescure, Rosalía Caballero, Mark Ebbert, Blanca Munárriz, Manuel Ruíz‐Borrego, Roy R. L. Bastien	2013	79
16	Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor–Positive Breast Cancer The Oncologist ·Catherine Margaret Kelly, Philip Seth Bernard, Savitri Krishnamurthy, Bailiang Wang, Mark Ebbert, Roy R. L. Bastien, Kenneth Michael Boucher, Elliana J. Young	2012	63
17	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype Acta Neuropathologica ·Shunsuke Koga, Naomi Kouri, Ronald L. Walton, Mark Ebbert, Keith A. Josephs, Irene Litvan, Neill R. Graff‐Radford, J. Eric Ahlskog	2018	63
18	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience Genome Medicine ·Perry G. Ridge, Celeste M M. Karch, Simon Hsu, Ivan Arano, Craig Carl Teerlink, Mark Ebbert, Josue D. Gonzalez Murcia, James M. Farnham	2017	60
19	DNA reference alignment benchmarks based on tertiary structure of encoded proteins Bioinformatics ·Hyrum D. Carroll, Wesley A. Beckstead, Timothy D. O’Connor, Mark Ebbert, Mark Clement, Quinn O. Snell, David A. McClellan	2007	56
20	Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro Molecular Neurodegeneration ·Mika P. Cadiz, Tanner D. Jensen, Jonathon P. Sens, Kuixi Zhu, Won‐Min Song, Bin Zhang, Mark Ebbert, Rui R. Chang	2022	51

About Mark Ebbert

Mark Ebbert is a scholar working on Cancer Research, Neurology, Neurology, Molecular Biology and Genetics, having authored 61 papers that have together received 4.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (7 papers), Alzheimer's disease research and treatments (7 papers), Bioinformatics and Genomic Networks (7 papers), Amyotrophic Lateral Sclerosis Research (6 papers), Genetic Associations and Epidemiology (6 papers), Neurogenetic and Muscular Disorders Research (4 papers), RNA Research and Splicing (4 papers) and Genomics and Phylogenetic Studies (3 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.0k citations), Neurology (311 citations), Neurology (397 citations) and Genetics (226 citations). Mark Ebbert has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Philip Seth Bernard, Inge J. Stijleman, Perry G. Ridge, Bryan E. Welm, Rachel E. Factor, Brett A. Milash, Robert Lor Randall, Saundra S. Buys, Leigh A. Neumayer and Yoko S. DeRose. Their work appears in journals such as BMC Genomics, BMC Bioinformatics, Molecular Neurodegeneration, Journal of Clinical Virology and Bioinformatics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark Ebbert

Impact in

Papers in i

In The Last Decade

Mark Ebbert

Mark Ebbert's Hit Papers

Peers

Countries citing papers authored by Mark Ebbert

Fields of papers citing papers by Mark Ebbert

All Works

About Mark Ebbert

Explore authors with similar magnitude of impact

Papers in